EBIO Profile
Eleven
Biotherapeutics, Inc. (EBIO) is a clinical-stage biopharmaceutical
company that is focused on developing innovative protein-based
therapies for the treatment of cancer and other diseases. The
company's product candidates are designed to target specific proteins
that are involved in the progression of certain diseases.
Eleven Biotherapeutics' lead product candidate is Vicinium, a
protein-based therapy designed to target and kill cancer cells in
patients with non-muscle invasive bladder cancer. The company is also
developing other product candidates, including a treatment for wet
age-related macular degeneration.
Eleven Biotherapeutics was
founded in 2010 and is headquartered in Cambridge, Massachusetts. As
of September 2021, the company was conducting clinical trials for its
product candidates and had not yet generated significant revenue. The
company's revenue for the fiscal year 2020 was $1.4 million,
representing a decline from $4.4 million in the previous year. Net
loss for the same period was $24.3 million, a decline from a net loss
of $34.9 million in the previous year.
Eleven Biotherapeutics
has a market capitalization of approximately $15 million as of my
knowledge cutoff of September 2021, and its stock is listed on the
NASDAQ stock exchange under the ticker symbol EBIO.
The
biopharmaceutical industry is subject to various risks, including
regulatory risks, competitive risks, and clinical trial risks.
However, Eleven Biotherapeutics' focus on developing innovative
protein-based therapies and its efforts to advance its product
candidates through clinical trials should position it for improved
performance in
|
